FDA clears Ipsen’s primary biliary cholangitis drug June 11, 2024 AutoBot News 0 Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).